Extracorporeal membrane oxygenation support in children with severe coronavirus disease-2019: A case series

Candice Torres de Melo Bezerra Cavalcante1,2, Andrea Consuelo de Oliveira Teles1, Isabel Cristina Leite Maia1

  • 1Hospital Dr. Carlos Alberto Studart Gomes, Av. Washington Soares, 1321 - Edson Queiroz, Fortaleza, CE CEP 60811-905, Brazil.

Insights

Extracorporeal membrane oxygenation (ECMO) provided life support for six children with severe COVID-19 respiratory failure. This pediatric ECMO case series showed a 66.7% survival rate, highlighting its potential in critical pediatric cases.

Area of Science:

  • Pediatric Critical Care Medicine
  • Infectious Diseases
  • Cardiopulmonary Support

Background:

  • COVID-19 predominantly impacts adults, with lower prevalence but potential for severe disease in children.
  • A subset of pediatric COVID-19 patients develop severe hypoxemic respiratory failure refractory to conventional treatments.
  • Extracorporeal membrane oxygenation (ECMO) is a potential rescue therapy for severe pediatric respiratory failure.

Purpose of the Study:

  • To report a series of six pediatric cases of COVID-19 requiring ECMO support.
  • To evaluate the outcomes of children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection treated with ECMO.
  • To assess the viability of ECMO as an intervention for refractory hypoxemic respiratory failure in children.

Main Methods:

  • Observational, retrospective case series.
  • Data collected from pediatric intensive care units between March 2020 and June 2021.
  • Analysis of sociodemographic, clinical, and laboratory data for children on ECMO.

Main Results:

  • Six children (median age 1.8 years) with severe COVID-19 respiratory failure received ECMO.
  • Mean ECMO duration was 11 days, with a mean ventilation time of 20.5 days.
  • Survival to hospital discharge was 66.7% (4/6), with one in-hospital mortality and one death post-decannulation.

Conclusions:

  • ECMO can be a life-saving intervention for select pediatric patients with severe COVID-19 and refractory hypoxemic respiratory failure.
  • Despite a 33.3% mortality rate in this series, ECMO offers a chance of survival when conventional therapies fail.
  • Further research is warranted to optimize ECMO use in pediatric COVID-19 critical care.
Abstract

Related Concept Videos

Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
399
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
356
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
219
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
362
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
254
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
331